Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility

2011 ◽  
Vol 90 (1) ◽  
pp. 117-125 ◽  
Author(s):  
M Dobrinas ◽  
J Cornuz ◽  
B Oneda ◽  
M Kohler Serra ◽  
M Puhl ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Genetic Polymorphisms ◽  
Cyp1a2 Activity

scholarly journals Genetic Polymorphisms in Dopamine-Related Genes and Smoking Cessation in Women

2006 ◽  
Vol 163 (suppl_11) ◽  
pp. S130-S130
Author(s):  
T G Ton ◽  
M A Rossing ◽  
D J Bowen ◽  
F M Farin
Keyword(s):  
Smoking Cessation ◽  
Genetic Polymorphisms

scholarly journals Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation

2020 ◽  
Vol 11 ◽  
Author(s):  
Ahmet Muderrisoglu ◽  
Elif Babaoglu ◽  
Elif Tugce Korkmaz ◽  
Mert C. Ongun ◽  
Erdem Karabulut ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Cytochrome P450 ◽  
Drug Treatment ◽  
Genetic Polymorphisms ◽  
Genetic Variants ◽  
Smoking Status ◽  
Turkish Population ◽  
Drug Transporter ◽  
Cytochrome P450 Enzymes ◽  
Quit Smoking

ObjectivesTo determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6, CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a Turkish population.Methods130 smokers and 130 non-smokers were recruited. Individuals who never smoked were described as non-smokers. 130 smokers were treated with nicotine replacement therapy (NRT) (n = 40), bupropion (n = 47), bupropion + NRT (n = 15), and varenicline (n = 28). Smokers were checked by phone after 12 weeks of treatment whether they were able to quit smoking or not. Genotyping and phenotyping were performed.ResultsCessation rates were as follows; 20.0% for NRT, 29.8% for bupropion, 40.0% for bupropion + NRT, 57.1% for varenicline (p = 0.013). The frequency of ABCB1 1236TT-2677TT-3435TT haplotype was significantly higher in non-smokers as compared to smokers (21.5% vs. 10.8, respectively; p = 0.018). Neither smoking status nor smoking cessation rates were associated with genetic variants of CYP2A6 (p = 0.652, p = 0.328, respectively), or variants of CYP2B6 (p = 0.514, p = 0.779, respectively).ConclusionGenetic variants of the drug transporter ABCB1 and the 1236TT-2677TT-3435TT haplotype was significantly associated with non-smoking status. Neither ABCB1 nor CYP2A6, CYP2B6 genetic variants were associated with smoking cessation rates at the 12th week of drug treatment.

Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population

2009 ◽  
Vol 10 (5) ◽  
pp. 769-778 ◽  
Author(s):  
Arzu Gunes ◽  
Gul Ozbey ◽  
Elif Hilal Vural ◽  
Canan Uluoglu ◽  
Maria Gabriella Scordo ◽  
...  
Keyword(s):  
Genetic Polymorphisms ◽  
Turkish Population ◽  
Cyp1a2 Activity ◽  
Gender And Age

The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis

2017 ◽  
Vol 18 (6) ◽  
pp. 760-768 ◽  
Author(s):  
Nut Koonrungsesomboon ◽  
Rapheephorn Khatsri ◽  
Penwisa Wongchompoo ◽  
Supanimit Teekachunhatean
Keyword(s):  
Systematic Review ◽  
Genetic Polymorphisms ◽  
Meta Analysis ◽  
Cyp1a2 Activity ◽  
The Impact

Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers

2008 ◽  
Vol 18 (1) ◽  
pp. 11-16 ◽  
Author(s):  
Doug-Hyun Han ◽  
Keun-Ho Joe ◽  
Chul Na ◽  
Young-Sik Lee
Keyword(s):  
Smoking Cessation ◽  
Genetic Polymorphisms

scholarly journals Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study

2007 ◽  
Vol 3 (1) ◽  
pp. 22 ◽  
Author(s):  
Thanh GN Ton ◽  
Mary Rossing ◽  
Deborah J Bowen ◽  
Sengkeo Srinouanprachan ◽  
Kristine Wicklund ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Cohort Study ◽  
Genetic Polymorphisms ◽  
Prospective Cohort Study ◽  
Prospective Cohort
Sign in / Sign up

Export Citation Format

Share Document